Leriglitazone (MIN-102) is a revolutionary, selective PPAR gamma agonist designed to traverse the blood-brain barrier and deliver therapeutic effects directly to the central nervous system (CNS). This orally bioavailable medication distinguishes itself by demonstrating significant efficacy and a favorable safety profile in clinical trials for X-linked adrenoleukodystrophy (X-ALD) across both adult and pediatric populations. Its mechanism involves modulating critical pathways to mitigate mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination, and axonal degeneration. Supported by robust preclinical evidence and protected by patents until 2039, Leriglitazone holds promise as a best-in-class treatment for a variety of CNS diseases, marking a significant leap forward in neurotherapeutic care.

Basic information

Country

SPAIN

Group Name

Minoryx Therapeutics

Source

Source